Pharmicell Expands Supply of Simzia Raw Materials to Multinational Pharmaceutical Company UCB

Pharmicell announced on the 19th that it will supply the pharmaceutical intermediate mPEG to the Belgian multinational pharmaceutical company UCB.

Earlier, UCB's operational team inspected the factory facilities for mEG-OH (20K) supplied to UCB in April. They visited the Biochemical Ulsan Plant 1 to receive quality certification and expanded orders.

The expanded orders include UCB's flagship product 'Simzia,' a TNF-α inhibitor for the treatment of autoimmune diseases. Its sales reached 2 billion euros (approximately 2.7 trillion KRW) in 2022. Pharmicell, one of UCB's major suppliers, provides the raw material mPEG used in this product.

A Pharmicell representative stated, "Since starting commercial supply of mPEG used in the production of UCB's flagship product 'Simzia' in 2020, we have received quality certification from UCB, leading to increased order volumes. We expect the sales of the single mPEG product to double from last year's sales of 4.9 billion KRW."

He added, "With the normal operation of Ulsan Plant 1, we plan to supply products without disruption to major clients including UCB, Germany's Merck, Necta, and Sunbio."

mPEG is used as a carrier for effective delivery of protein-based new drugs through the drug delivery technology called 'Pegylation.' Pegylation refers to the technique of binding PEG to proteins to enhance the efficacy of protein-based drugs and suppress resistance during continuous use.

This content was produced with the assistance of AI translation services.